Pre-Open 11/20: (ARAV) (I) (TGT) Higher (PDD) (URBN) (MUX) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Organogenesis Holding (ORGO) Prices 9M Share Common Offering at $5/Sh
November 22, 2019 5:36 AM ESTOrganogenesis Holdings Inc. (NASDAQ: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the pricing of an underwritten public offering of 9,000,000 shares of its Class A common stock,... More
CRISPR Therapeutics (CRSP) Prices 4.25M Share Common Offering at $64.50/Sh
November 21, 2019 5:52 AM ESTCRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,250,000 common shares at a public offering price of $64.50 per share. In addition, the underwriters have a 30-day... More
Lowe's (LOW) PT Raised to $134 at RBC Capital; Remain 'Aggressive Buyers'
November 20, 2019 1:22 PM ESTRBC Capital analyst Scot Ciccarelli raised the price target on Lowe's (NYSE: LOW) to $134.00 (from $129.00) while maintaining a Outperform rating following results.
The analyst commented, "Lowes US comp results of +3% were a bit better than investor expectations following Home Depots report... More
Aravive Inc. (ARAV) PT Raised to $31 at H.C. Wainwright
November 20, 2019 12:14 PM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Aravive Inc. (NASDAQ: ARAV) to $31.00 (from $18.00) while maintaining a Buy rating.
The analyst commented, "This morning, Aravive announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of... More
